Pregabalin 150 mg Capsule
Pregabalin 150mg
Hard capsule · Prescription medication
U & Life Science Co., Ltd.
MFDS item code 202003821 · Approved 2020.05.26
This product's status changed to Approval withdrawn on 2025.02.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures
This medicine is used in adults for the treatment of peripheral and central neuropathic pain. It is also utilized as an adjunctive treatment for patients with epilepsy who experience partial seizures, especially those accompanied by secondary generalized symptoms or not. Additionally, it is effective in alleviating symptoms of fibromyalgia. Therefore, this medication is used to manage neuropathic pain and epileptic seizures and to improve symptoms of fibromyalgia.
This drug is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys unchanged. Since the clearance of this drug is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. For women, multiply the result obtained from the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: An additional dose refers to a supplemental dose administered as a single dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age and adolescents aged 12-17 years: Use is not recommended because sufficient safety and efficacy data are not available.
This drug may increase the risk of suicidal thoughts or actions, and if there are any changes in mood or behavior during treatment, medical personnel should be informed immediately. This drug should not be used in patients with hypersensitivity to the ingredients or certain hereditary lactose intolerance. Diabetic patients should be cautious of weight gain and changes in blood sugar, and may need dose adjustments of antidiabetic medications. If symptoms of angioedema occur, the medication should be discontinued immediately. Elderly patients should be particularly cautious at the beginning of treatment due to the risk of injury from dizziness or drowsiness. Temporary visual obscurity or changes in vision may occur; consult medical personnel if any abnormal symptoms arise. Withdrawal symptoms such as insomnia, headaches, and anxiety may occur upon discontinuation, so medication adjustments should be discussed with healthcare providers. Patients with a history of drug abuse should be cautious due to the possibility of misuse of this drug. Patients with impaired renal function may require dose adjustments, and heart failure patients should use it cautiously. Co-administration with opioid analgesics may enhance central nervous system depression, so caution is advised. During early pregnancy, there is a risk of fetal malformation, so it should not be administered to pregnant women except in special cases, and women of childbearing potential should use effective contraception. Breastfeeding women should consider discontinuation of breastfeeding or the medication due to the possibility of the drug passing into breast milk. It is advisable to avoid hazardous activities like driving or operating machinery until dizziness or drowsiness resolves after taking this medication. Severe skin reactions may occur, so if there are any symptoms of skin abnormalities, the medication should be stopped immediately and medical personnel consulted. Overdose may result in drowsiness, confusion, depression, and may require treatment such as hemodialysis. This drug should be kept out of reach of children and should not be transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture; therefore, it should be stored in a tightly closed container. It is important to maintain a storage temperature between 15 and 30 degrees Celsius. Proper storage helps maintain the effectiveness and safety of the medication.
A white hard capsule filled with white powder
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 150mg
Hard capsule · Prescription medication
U & Life Science Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.